Pediatric HIV/AIDS in Sub-Saharan Africa: Emerging issues and way forward

Background: Sub-Saharan Africa has the largest burden of pediatric HIV in the world. Global target has been set for eradication of pediatric HIV by 2015 but there are still so many complex issues facing HIV infected and affected children in the sub-continent. Objective: To review the current and emerging challenges facing pediatric HIV care in sub-Saharan Africa; and proffer solutions that could help in tackling these challenges. Method: A Medline literature search of recent publications was performed to identify articles on “pediatric HIV”, “HIV and children”, “HIV and infants”, “HIV and adolescents” in sub-Saharan Africa. Result: There are a number of challenges and emerging complex issues facing children infected and affected by HIV in sub-Saharan Africa. These include late presentation, limited access to pediatric HIV services, delayed diagnosis, infant feeding choices, malnutrition, limited and complex drug regimen, disclosure, treatment failure and reproductive health concerns. A holistic cost effective preventive, diagnostic and treatment strategies are required in order to eliminate pediatric HIV in SSA. Conclusion: HIV infected children and their families in sub-Saharan Africa face myriad of complex medical and psychosocial issues. A holistic health promotional approach is being advocated as the required step for eradication of pediatric HIV in Africa.

Medline through PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) was searched for articles on HIV and pediatric HIV in sub-Saharan Africa. Search was limited to English-language publications, and used the following search strategy: ((Pediatric HIV) OR (HIV and children) OR (HIV and infants) OR (HIV and adolescents) OR (PMTCT) OR (sub-Saharan Africa) OR (OVC)) AND (epidemiology) OR (risk) OR (determinant) OR (incidence) OR (prevalence). The references of retrieved were inspected; and additional relevant articles were selected and reviewed. The HIV epidemic may be stabilizing but millions are still living with the virus in SSA. South Africa has the largest HIV disease burden in the world with a median sero-prevalence of 30% and over 40% in KwaZulu-Natal7. The Pediatric AIDS Clinical Trial Group (PACTG) 076 clinical trial was the first study to demonstrate that zidovudine (AZT) starting at 14 weeks gestation, intravenous in labor and for 6 weeks to the infant post-natally reduced vertical transmission by 67%11. Research has shown that with efficacious interventions, the risk of MTCT can be reduced to 2%7. However, it was noted in 2004 that despite multiple HIV programs in Africa, the number of HIV infected pregnant women who utilize them is less than 5%12. While, there have been success stories coming out of Africa with respect to the PMTCT programs, the vast majority of the affected do not have access to these programs7. Studies have also demonstrated the benefits of early care and antiretroviral therapy in reducing morbidity and mortality in HIV infected children13,14,15. This informed the World Health Organization (WHO) policy statement that all HIV infected children less than 24 months be commenced on highly active anti-retroviral therapy (HAART) as soon as HIV diagnosis is made. Surprisingly, HIV infected children still present late at health facilities16. Virologic testing for confirming HIV infection in children less than 18 months is still a challenge. While antibody testing is unreliable, virologic testing is not yet widely available in SSA. In most of the countries of SSA, DNA PCR testing is restricted to tertiary health facilities8. Other facilities are required to collect sample as dried blood spot (DBS) and log them to bigger facilities that have DNA PCR machine. Only few countries like Botswana can currently boost of wide spread access to dried blood spot (DBS) testing 6 This increases the turn-around time for returning test results. Even the facilities that have the machines rarely return results promptly. Other challenges and concerns include drug related, psycho-social, reproductive health concerns, infant feeding choices and lack of effective HIV vaccine. These are discussed further. The ARVs may be free in most settings but some families still travel long distances to receive care and treatment 17. Often times, appointments and subsequently ARV medications are missed because of lack of resources for transportation which leads to loss to follow up17. A multi-center study involving six West African countries and 2170 HIV infected children on ARVs documented a program loss to follow up of 23.1% at one year18. The figure will likely be higher as these children stay longer in the program. It is also not uncommon to see young children and adolescents on ARV who are unaware of why they are on these drugs. Most times, parents and caregivers shy away from issues of HIV disclosure to infected children despite possible benefits. In another multi-center study involving 650 adolescents aged 10 to 21 years in three West African countries (Côte d’Ivoire, Mali and Senegal), two-third of the HIV-infected adolescents on ART were not aware of their HIV status but disclosed HIV status improved retention in care19. In Addis Ababa, a cross-sectional survey involving 172 parents/caregivers of HIV-infected school-age children showed that only 16.3% of HIV-infected school children knew their diagnosis20. Non -HIVdisclosure to children has implications for adherence to therapy, resistance and treatment failure. Haberer et al21 in a study in Zambia noted that older children (9–15 years) with no knowledge of their HIV diagnosis are at risk of treatment failure due to poor adherence. Poor adherence to ARVs for whatever reason contributes to drug resistance and treatment failure. Studies have shown rising rate of first-line treatment failures among children on ARVs22. In the event of treatment of failure, there aren’t too much other available ARV options. Another devastating psycho-social issue is stigma and discrimination which has remained pervasive in most African countries23. It is a powerful barrier to scaling up and increasing access to PMTCT and pediatric HIV diagnosis, treatment, and care23. Stigma and discrimination can contribute to non-adherence and non-disclosure, thereby potentially increasing the risk of treatment failure. Although the majority of SSA countries have moved to pediatric treatment options that considers maternal and infant exposure to PMTCT 24, there are still challenges with complex ARV regimens, pill burden, drug storage and palatability, drug stockout, treatment interruption or poor adherence, poor retention on first line ARV regimen, lost to follow-up, treatment failure and HIV drug resistance in the pediatric population8,25. Resistance to commonly used drugs such as nevirapine and ritonavir has been widely reported among African children on first or second line ART11,12 but less with Efavirenz and LPV/r26,27 Malnutrition and infections interacts with HIV disease in a complex cyclical way to contribute to significant morbidity and mortality28–30. There is still an unacceptable high burden of malnutrition in countries of Africa31,32, as well as preventable diseases like malaria, tuberculosis, diarrhea diseases and acute respiratory tract infections. Severe respiratory tract infections and malnutrition have been shown to be associated with increased HIV mortality28–30. Malnutrition among HIV infected children epitomizes the level of hunger and poverty in Africa. The use of Ready-to-Use Therapeutic foods such as plumpy nuts to combat severe acute malnutrition (SAM) in HIV infected children is commendable but again, it is largely donor driven33. One of the greatest reproductive health concerns of HIV infected women is how to ensure HIV free survival for their babies. Infant feeding choices in the context of HIV has particularly been a debated issue. The WHO 2010 Rapid Advice on HIV and infant feeding is a welcome development and promises to reduce the morbidity and mortality associated with not breastfeeding children in the subcontinent34. This will however require further scientific evaluation such as acceptance rate by mothers, adherence of mother/child pair to antiviral prophylaxis during the breastfeeding period, possibility of nevirapine resistance in future and eventual outcome in terms of infection rate, morbidity and mortality. A recent study in Zimbabwe noted that implementing the 2010 Rapid Advice could substantially reduce infant HIV infection but will fall short of WHO target MTCT risk of less than 5% unless strategies that improve PMTCT uptake, retain women in care, and support medication adherence throughout pregnancy and breastfeeding are put in place10. Another option currently on the table but has not been recommended formally is triple ARVs for HIV infected pregnant women starting as soon as HIV is diagnosed, regardless of CD4 count, and continued for life while the infant receives daily NVP or AZT from birth through age 4–6 weeks regardless of infant feeding method35. As HIV infected children transit to adolescents and young adults, there is also the delicate balancing of their sexual and reproductive health needs on one side and the avoiding risk of HIV super-infection, infecting others and MTCT. The greatest challenge facing HIV services in SSA is the issue of sustainability when donors withdraw their supports. With the economic down turn around the world and rising domestic challenges within donor countries, the question is not if, but when will the donors pull out. More than a decade after the Abuja declaration that member nations of the African Union should increase health expenditure to 15%, only few countries have honored that commitment [36]. Unacceptable high levels of corruption within and outside the governments still exist resulting in persistent poor health care delivery in the continent37,38. The government of African nations should rise and not only contribute resources to fighting HIV/AIDS but also strengthen their health systems in line with international standards. The future fight against pediatric HIV in SSA should focus on cost effective preventive strategies. HIV/AIDS is as much a social problem as it is a medical problem. Eliminating pediatric HIV in SSA will require a health promotion approach that involves combination of the five models described by Naidoo and Willis39. These five models are medical, educational, behavioral, social or radical change and empowerment39 and if collectively applied will provide a holistic intervention towards near or total elimination of pediatric HIV in Africa. In the medical model, we need to ensure universal access of evidence based scientific interventions that could prevent MTCT of HIV. Every pregnant woman in the SSA should have access to PMTCT services including family planning within walking distances in their communities. Those that are HIV infected should be guaranteed a continuum of care for themselves and their babies. DNA PCR technology should be scaled up to provide a wider coverage and reduce the turnaround time of retrieving test results to days. There is therefore, the need for research to produce cheaper technologies for DNA PCR testing or suitable alternative rapid tests with high sensitivity and specificity. This is one sure step towards effective implementation of the new WHO policy of early anti-viral therapy for infected children. In a recent study designed amongst other things to assess the accuracy of 5 rapid tests for detecting HIV exposure, Sherman et al40 found that only Insti HIV-1 (BioLytical Laboratories, British Columbia, Canada) fulfilled the WHO recommendation of a minimum sensitivity of 99% and specificity of 98%24,35 although the authors recommended further evaluation in infants. Recent evaluation has also demonstrated that inexpensive, portable and battery-operated point-of-care CD4+ T cell testing technologies showed high sensitivity and negative predictive value41. This can potentially help in reducing delays in linkage to care and ART initiation at the community level. We also need more focused research in the area of cheaper and more palatable but effective first and second line anti-retro-virals with reduced dosing frequency and minimal drug-drug interactions. Scaling up of pediatric ART treatment in SSA need to urgently consider simple fixed-dose combinations and child-friendly adapted formulations, such as dispersible tablets, improved palatability and heat stable formulations. Examples include the need for ritonavir-boosted atazanavir and heat-stable ritonavir-boosted lopinavir in palatable pediatric formulations42. With the rising number of treatment failures among children on ARVs in SSA26,27,42, there is the need to improve treatment failure detection. The use of clinically validated, kit-based genotyping assays in SSA limit HIV drug resistance testing due to cost and the possible lack of a steady supply of test reagents29. The alternative use of dried blood spots promises to be a more cost effective alternative. A recent clinical trial that compared DBS testing and conventional plasma genotypes reported a 100% concordance43. However, further research will be required in this area. It is also interesting to note that micronutrients may have significant roles in reducing the burden of HIV. A recent clinical trial in Tanzania involving 884 HIV infected pregnant women showed that children born to women with low vitamin D levels had a 61% higher risk of dying during follow up44. Cautiously though, while vitamins B, C, D and E have been found to delay HIV disease progression, a review has noted that vitamin A could double the risk of mortality in infants exposed to HIV via breastfeeding and high dose of zinc may have a positive effect on production of infectious virus through its action on the reverse transcriptase enzyme45,46. The capacity of every health care worker therefore, should be built to be able to identify and manage HIV infected/affected children and their families. We need to move from the current HIV stand-alone services to an approach that is integrated with the management of other maternal and childhood diseases47. With the current human resource for health crises in SSA, an effective strategy to pediatric HIV scale up, follow up and improved retention will be decentralization and task shifting48. A systematic review has shown that task shifting of some HIV services offers high-quality, cost-effective care to more patients than a physician-centered model48. There is an overlap of behavioral and social change models; and one can influence the other. We need to address the several cultural and anthropological issues that fuel HIV vertical transmission and militate against pediatric management of HIV/AIDS in SSA. These include gender inequality, trans-generational sex, premarital sex, unprotected and dry sex, multiple sexual partners, and “widow cleansing”49–51. In countries like Cote d’ Ivoire, Uganda and Rwanda, the rate of unintended pregnancies among HIV positive women is considerable high but avoidable52. The other aspect that requires urgent attention is unregulated complementary and alternative practices that delay/discourage prompt access to and continued HIV care/services49. Charlatans that prescribe sex with virgins and children as a cure for HIV are helping to increase HIV transmission49. Perhaps, no other disease has brought out the need to empower families as a disease preventive strategy like HIV. HIV wears the mask of illiteracy and poverty to create a vicious cycle53,54. Educating the youths especially girls will mean greater awareness of health and their health needs, possible better jobs and guaranteed economic empowerment later in life. It is also important that pregnant women are constantly educated on the best practices to limit MTCT using the health facilities and other resources within the community such as peer counselors to support exclusive breastfeeding, support groups and community based organizations55. HIV infected children need to better understand their infection and manage their status using various coping strategies such as peer support groups, selective disclosure, religion and acceptance56. Radical changes need to happen in order for the continent to be able to control the HIV scourge. Allocation of national resources to pediatric HIV/AIDS has often failed to keep pace with the need and this gap should be addressed. The whole health systems in SSA is in dire need of overhaul and is characterized by out of pocket payments for health services,, inefficient health insurance policies, decayed and dilapidated infrastructures at health institutions and lack of substantial investment in human resource for health57,58. In terms of funding, the rest of SSA should borrow a leaf from Kenya, Namibia, Sierra Leone and Uganda; where domestic spending on HIV/AIDS rose by more than 100 percent between 2006 and 201159. In Botswana, Comoros, Mauritania, Mauritius, the Seychelles and South Africa, domestic investment accounted for more than 70 percent of AIDS funding38,59. This is commendable but needs to be cascaded in the SSA’s entire health systems in order to not only eliminate pediatric HIV but also achieve the millennium development goal 4 of a two thirds reduction in child mortality by 201560.

N/A

• Dima Health